Corey S. Cutler, MD, MPH, FRCPC; Yi-Bin Chen, MD; and Haris Ali, MD, review currently available treatment options for acute and chronic GVHD and discuss the management of steroid-refractory disease.
EP. 1: Overview of Graft-Versus-Host Disease
EP. 2: Diagnosis of Acute and Chronic GVHD
EP. 3: Role of GVHD Prophylaxis
EP. 4: Initial Therapy in GVHD
EP. 5: Treatment for Steroid-Refractory Acute GVHD
EP. 6: Treatment for Steroid-Refractory Chronic GVHD
EP. 7: Emerging Therapies for Acute and Chronic GVHD
EP. 8: Unmet Needs in GVHD
Benefit of Elacestrant Improves With Longer Duration of CDK4/6 Inhibition in Patients With ER+/HER2– Metastatic Breast Cancer
Lifileucel Induces Response in Metastatic Melanoma Independent of Number of IL-2 Doses Received
Rajkumar Previews CAR-T Updates, Elranatamab Findings in Multiple Myeloma Ahead of ASH 2022
Palbociclib Plus Fulvestrant Fails to Improve PFS in ER+/HER2- Breast Cancer After Progression on a CDK4/6 inhibitor
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.